Page 68 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Chapter 4
been described previously (7-9). Harmonization of quantitative 89Zr-immuno- PET imaging has also been reported, allowing for broad scale application, e.g. in a multi-center setting (10).
Before starting clinical 89Zr-immuno-PET trials, the following conditions are essential to allow appropriate interpretation of data. Prerequisites are that the radioimmunoconjugate of interest is stable and has the same binding and biodistribution characteristics as the unlabeled parental mAb. Imaging procedures should be standardized and validated in order to provide reliable quantification. Assuming these requirements are fulfilled, biodistribution and tumor uptake of a 89Zr-mAb, defined on PET, can be used as an imaging biomarker for tumor targeting of the “cold” therapeutic antibody.
Until now, at least 15 clinical 89Zr-immuno-PET trials have been reported, see Table 1, providing first information on the clinical performance of 89Zr- immuno-PET. Therefore, evaluation of the potential and current limitations of this novel imaging technique seems timely to enable optimal design of future trials. This review summarizes the results from initial clinical 89Zr-immuno-PET in oncology, and technical aspects of trial design are discussed.
Table 1. Summary of clinical studies on 89Zr-immuno-PET in oncology
Author
Börjesson
Dijkers
Rizvi Gaykema
van Zanten van Asselt Bahce Pandit-Taskar
Den Hollander Gaykema
Gebhart Lamberts
Menke-van der Houwen van Oordt
Muylle Oosting
Year Target
2006 CD44v6 2009
2010 HER2
2012 CD20
2013 VEGF-A
2013 VEG-F
2014 VEGF-A
2014 VEGF-A
2014 PSMA 2015
2015 TGF-β
2015 HER2
VEGF-A bevacizumab
mAb
cmAb U36
trastuzumab ibritumomab-tiuxetan bevacizumab bevacizumab bevacizumab bevacizumab
Hu-J591
fresolimumab
Tumor type N
Head and neck cancer 20
Breast cancer 14 B-cell lymphoma 7 Breast cancer 23 Glioma 3 Neuroendocrine tumors 14 Non-small cell lung cancer 7 Prostate cancer 50
Glioma 12
Breast cancer 10 6
Breast cancer 56
Pancreatic cancer 11 Ovarian cancer 4
Colorectal cancer 10
B-cell lymphoma 5 Renal cell carcinoma 22
2015 HER2 2015 MSLN
2015 EGFR
2015 CD20 2015 VEGF-A
trastuzumab MMOT0530A
cetuximab
rituximab bevacizumab
trastuzumab
66